Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Avalanche Biot Cm ST (AAVL)

Avalanche Biot Cm ST (AAVL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Avalanche Biot Cm ST 1035 O BRIEN DRIVE SUITE A MENLO PARK CA 94025

www.avalanchebiotech.com P: 650-272-6269

Description:

Avalanche Biotechnologies, Inc. is a biotechnology company. It engages in developing gene therapies for the treatment of ophthalmologic disorders. The Company's products under development includes AVA-101, AVA-201, AVA-311, AVA-322 and AVA-323. Using a next generation gene therapy platform, the Ocular BioFactory (TM), the Company is developing products designed to provide long-term benefit or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye. Avalanche Biotechnologies, Inc. is headquartered in Menlo Park, California.

Key Statistics

Overview:

Market Capitalization, $K 117,210
Shares Outstanding, K 25,760
Annual Sales, $ 2,320 K
Annual Net Income, $ -47,450 K
Last Quarter Sales, $ 960 K
Last Quarter Net Income, $ -14,090 K
60-Month Beta 2.43
% of Insider Shareholders 15.20%
% of Institutional Shareholders 59.64%

Growth:

1-Year Return -88.12%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 05/11/16
Earnings Per Share ttm -1.76
EPS Growth vs. Prev Qtr 18.18%
EPS Growth vs. Prev Year 2.17%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

AAVL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -19.77%
Return-on-Assets % -18.89%
Profit Margin % -2,045.26%
Debt/Equity 0.00
Price/Sales 61.96
Price/Cash Flow N/A
Price/Book 0.42
Book Value/Share 9.81
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar